The FDA released a report to help health care providers discuss Risk Evaluation and Mitigation Strategy (REMS) programs with their patients. “A Framework for Benefit-Risk Counseling of Patients Taking Drugs with a REMS” outlines principles, best practices and examples that help underscore the importance of taking an individualized and collaborative counseling approach when discussing drugs with REMS.
Read more here.